Physician profile
Robert Dyer
NPI 1467983494
$662.29
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $290 · 2023: $298 · 2024: $73.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $372.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $371.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $161.76 | 2022-2023 | Evenity, Prolia, Enbrel |
| Radius Health, INC. | $134.28 | 2022-2023 | Tymlos |
| Ani Pharmaceuticals, INC. | $52.33 | 2023 | Purified Cortrophin Gel |
| Genentech USA, INC. | $46.97 | 2022-2023 | Actemra |
| Janssen Biotech, INC. | $41.41 | 2022 | |
| Novartis Pharmaceuticals Corporation | $37.90 | 2022 | |
| Collegium Pharmaceutical, INC. | $36.92 | 2024 | Belbuca, Xtampza |
| Kyowa Kirin, INC. | $33.05 | 2023-2024 | Crysvita |
| Depuy Synthes Sales INC. | $32.97 | 2022-2023 | Monovisc, Orthovisc |
| Alexion Pharmaceuticals, INC. | $24.98 | 2023 | Ultomiris |
| Kiniksa Pharmaceuticals, LTD. | $20.86 | 2023 | Arcalyst |
| Aurinia Pharma U.S., INC. | $19.57 | 2023 | Lupkynis |
| Sandoz INC. | $19.29 | 2024 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Dyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.